Introduction
Many pulmonary inflammatory processes are accompanied by increased mucus secretion. Mechanisms currently recognized as being capable of stimulating mucus secretion from human airways include mast cell-derived mediators of allergy (1) (2) (3) (4) (5) , neurohormones (1, (6) (7) (8) , oxidative derivatives of arachidonic acid (2) (3) (4) (5) 9) , serum (10) , and Pseudomonas aeroginosa filtrates (I 1). Very recent studies indicate that activated human pulmonary macrophages synthesize and release a factor termed macrophage-derived mucus secretagogue (MMS) ' (12) that can stimulate mucus secretion in vitro. Since alveolar macrophages are derived from circulating blood monocytes (13, 14) , it was The Journal of Clinical Investigation, Inc.
Volume 75, January 1985, [191] [192] [193] [194] [195] [196] [197] [198] of interest to examine whether human peripheral monocytes might also be capable of influencing mucus secretion. All other materials were obtained as cited (12) .
Monocyte cultures
Monocytes were prepared by three different methods.
Ficoll-Hypaque density gradient (sp gr 1.074-1.078) separation (15). Heparinized peripheral blood from normal donors was first centrifuged at 500 g for 10 min at 220C. The buffy coat was then layered onto Ficoll-Hypaque, the preparation was centrifuged at 500 g for 20 min at 220C, and the mononuclear cells were removed from the interface. The cells were then washed three times in Hanks' balanced salt solution without Ca2l or Mg2" and resuspended in CMRL-1066 medium with penicillin (100 U/ml), streptomycin (100 Ag/ml), and L-glutamine (100 mM) without supplementary serum.
The concentration of peripheral monocytes was adjusted to 3-3.5 X 106 cells/2 ml. Cells were allowed to adhere to plastic dishes for 4 h and then washed vigorously three times with serum-free medium to remove nonadherent cells. The adherent cells were incubated for 24 h in CMRL-1066 without serum at 37°C in a humidified atmosphere of 5% CO2 before starting the experiments. The viability of the cells, which always exceeded 98%, was assessed by trypan blue dye exclusion after incubation in a 1% solution of the dye. Differential counts (Wright-Giemsa-stained cytocentrifuge preparations) revealed that the final cell preparation consisted of >90% monocytes and <10% lymphocytes. Adherent cells phagocytized both latex particles and activated zymosan (Sigma Chemical Co., St. Louis, MO) and stained positively for nonspecific esterases (16) .
Platelet-free human mononuclear cells. The usual Ficoll-Hypaque isolation procedures produce mononuclear cells contaminated with 10-1000 platelets/mononuclear cell (17) . To reduce platelet contamination, a recently described technique was used (17) . Briefly, EDTAanticoagulated blood was first centrifuged through Hypaque (sp gr 1.060) at 400 g for 5 min at 22°C followed by the usual FicollHypaque (sp gr 1.077) gradient. This procedure reduced platelet contamination to <I platelet/two mononuclear cells (17) . After the initial isolation, the cells were processed and cultured as described (18) . The purity of the monocytes was >95% as determined by both morphology and nonspecific esterase staining.
After the initial isolation, the cells were cultured as described above.
Preparation ofhuman airways for culture 
Zymosan preparation
Zymosan particles were suspended in sterile saline, boiled three times for 5 min, and washed three times with 30 vol of saline. The particles were then suspended in a ratio of 1:1 in normal human serum and incubated for 30 min at 37°C. The serum-treated zymosan particles were washed three times with 30 vol of 0.15 M NaCl and finally resuspended in the incubation buffer prior to their use. Nonactivated zymosan was handled in an identical fashion except that these particles were not exposed to serum. Either activated zymosan or nonactivated zymosan was added to the cells in culture at a ratio of 150 particles per monocyte. Supernatants were removed at different intervals (as indicated), pooled, centrifuged (3,000 g at 22°C for 10 min), filtered through 0.22-Am Millex-GV sterilizing filter units (Millipore Corp., Bedford, MA), and applied to airways in culture, usually adding 2 mI/ plate, at the beginning of period II. An alternative experimental design was also employed in which monocytes were incubated with activated zymosan (10 mg/ml) for 60 min; the cultures were then washed extensively to remove free zymosan, and the incubation was continued for 8 h. Finally, the supernatant was processed in a fashion identical to that described above.
Preparation of various particles for phagocytosis
Latex beads (polystyrene, average diam, 1.1 tm; Sigma Chemical Co.) were washed three times in saline before use. Preparations of formalinfixed Staphylococcus aureus containing protein A (Bethesda Research Laboratories, Bethesda, MD) were washed five times in saline, resuspended at a 2% concentration in saline, and added to cultured monocytes at 10 bacteria per monocyte. S. aureus that were deficient in protein A were handled in an identical fashion.
Determination if monocyte-derived mucus secretagogue is preformed or newly synthesized Peripheral monocytes were isolated and divided into two portions, each having 30 X 106 cells. One portion of cells was frozen in culture media at -70'C immediately after isolation. The other portion was cultured, incubated with activated zymosan or S. aureus for I h, and washed and cultured for 8 additional h. After the supernatants were collected, the cells were removed from the culture plates with a rubber policeman and frozen at -70'C. Thereafter, the cultured monocytes and the cells that had been frozen directly after isolation were handled in parallel. The monocytes were freeze-thawed three times, sonicated in ice (3 min at power setting 3) with the use of a microtip (model WI 85-F Heat Systems-Ultrasonics, Inc., Plainview, NY), and centrifuged at 3,000 g for 15 min at 4VC. The Iysate was filtered in the cold through 0.22-im membranes and added to airways in culture to assess mucus-secretagogue activity.
Partially purified MMS was obtained by ultramembrane filtration, gel filtration, and isoelectric focusing (see below). The MMS was then mixed with monocyte lysates for 4 h at 370C, filtered on 0.22-,gm membranes, and added to airways in culture.
In a related experiment, mononuclear cells were cultured in the presence (or absence, in parallel) of cycloheximide at 10 Ug/ml (Sigma Chemical Co.) for 16 h. These sets of cells were then exposed to activated zymosan or S. aureus for I h, after which the cultures were washed and the cells cultured for an additional 8 h. The supernatant was assayed for MMS activity. The cells were removed from the plates, freeze-thawed, sonicated as described above, and assayed for mucussecretagogue activity.
Relationship between eicosanoids and monocyte-derived mucus secretagogue Supernatants rich in mucus-secretagogue activity were prepared by incubating mononuclear cells with activated zymosan as described above. Such supernatants were adjusted to pH 3.0 with citric acid and extracted three times with 3 vol each of ethyl acetate or diethylether. The organic phase of each extraction was combined, evaporated to dryness under nitrogen, and resuspended in tissue culture medium before being assayed for mucus-secretagogue activity.
Supernatants rich in MMS activity were partially purified by ultramembrane and gel filtration (see below). These partially purified preparations were assayed by radioimmunoassay for the presence of prostaglandin E (PGE), PGF2,, and thromboxane B2 (20). As used for this study, these assays were sensitive to 2.5 pg.
Partial purification ofMMS 50 ml of MMS-rich supernatant was obtained from mononuclear cells incubated with activated zymosan. These supernatants were pooled and sequentially filtered on ultramembranes (YM10, molecular weight exclusion -10,000; and UMO5, molecular weight exclusion '500) (Amicon Corp., Danvers, MA) in a stirred chamber under nitrogen pressure (50 psi) with water as the wash buffer. The UMOS retentate was concentrated to I ml, brought back to 50 ml with distilled water, and reconcentrated twice. The washed, concentrated UM05 retentate was Iyophilized and resuspended in I ml of culture medium. In these experiments, 20 jMl of the concentrate was added to the airways in culture to assess secretagogue activity. 50 ml of culture medium that had never been exposed to monocytes or that had been exposed to monocytes plus nonactivated zymosan was manipulated in parallel as controls.
Concentrated UM05 retentate material was filtered on a I X 60-cm Sephadex G-25 column (Pharmacia Fine Chemicals, Pistcataway, NJ) at 4°C, and fractions of 1.2 ml were collected. Each fraction was separately filtered through 0.22-Mum membranes, Iyophilized, resuspended in I ml of distilled water, and refiltered. 20 Ml of this material was then added to the airways in culture. For isoelectric focusing, the active fractions were pooled (usually 2-4 ml), Iyophilized, and resuspended in I ml of water. I ml of fractionated MMS material was mixed with 58 ml of Buffalyte solution (pH 3-10) (Pierce Chemical Co., Rockford, IL) and III g of Pevikon (Accurate Chemical and Scientific Corporation, Westbury, NY). The slurry was poured into a horizontal isoelectric focusing apparatus (LKB electrofocusing kit, LKB Instruments, Inc., Gaithersburg, MD), and, with the method of Harpel and Kuppers (21), a pH gradient was established in 4 h at a constant power of 400 W (LKB 2197 power supply). The anodal and cathodal solutions were 0.1 M phosphoric acid and sodium hydroxide, respectively. The slurry was divided into 15 fractions that were poured individually into I X 6 columns and washed with 4 ml of water. The eluates were Iyophilized, resuspended in 0.5 ml ofwater, and individually filtered over I x 60-cm Sephadex G-25 columns as described above.
Statistics
The results are expressed as percent increase in mucous glycoprotein release as compared with control, as described in detail (2) . Each experiment used quadruplicate airway cultures for the determination of each point, and all results represent data observed from several experiments. The results are generally provided as the mean±SEM. Statistical comparisons were derived from paired sample t tests. (Fig. 2) . Within 4 h of incubation, the cultures showed evidence of MMS release, which plateaued between 6 and 16 h. The time course study for MMS release was repeated on several other occasions, and the cultures exposed to zymosan for 24 h appeared to have less activity than those at 4-16 h. Therefore, 4-8-h incubations of mononuclear cells with activated zymosan were considered optimal for MMS release. Results
Effects of zymosan on the release of MMS. To examine whether supernatants from peripheral monocytes might influence mucus secretion, 3 X 106 monocytes/plate were exposed to either nonactivated zymosan particles (10 mg/ml) or activated zymosan particles. After 8-h incubation, the supernatants were collected and added to cultured human airways that were secreting [3H]glucosamine-labeled mucous glycoproteins. As shown in Table I , the supernatants from monocytes cultured with nonactivated zymosan had no significant effect on airway mucus release (-7±2.6%, n = 5). By contrast, the supernatants from monocytes incubated with opsonized zymosan increased mucus release by 45.8±5.0% (n = 5, P < 0.001). The enhancing effects on mucus secretion by the factor released by monocytes exposed to activated zymosan ranged from 22 to 59% above the control in these experiments. Neither activated nor nonactivated zymosan had any effect when added directly to airway cultures. The factor found in the supernatant from monocytes incubated with activated zymosan was present in every experiment and was not influenced by the procedure used to isolate the monocytes. Based on these observations, the factor causing increased mucus glycoprotein release was termed monocyte-derived mucus secretagogue (MMS).
Dose response of zymosan for MMS release. Monocytes were exposed to 0.01-100 mg/ml of activated zymosan for 8 h, and the supernatants were added to the airways (Fig. 1) . In each of two experiments (which are pooled in Fig. 1 Effect of washing monocytes on MMS release. Microscopic analysis of monocytes exposed to activated zymosan indicated that the zymosan was rapidly taken up by the cells. We therefore examined whether a short initial exposure to activated zymosan followed by a longer incubation (in order to optimize MMS release) might be an acceptable design. In these experiments, monocytes were exposed to activated zymosan for either 8 h (the usual experimental design) or for 1 h followed by washing and an additional 8-h incubation. Using this procedure, we compared the supernatants from three experiments, and each generated equivalent degrees of increased mucus release (+30.2±1.0% for continuous zymosan exposure and +29.7±1.4% for 1 h of zymosan exposure). Therefore, it appeared that peripheral monocytes generate equivalent amounts of MMS either in the continuous presence of activated zymosan or after a 1-h exposure.
Opsonization and phagocytosis. To analyze the requirements for zymosan activation, zymosan was exposed to human sera that had been heat inactivated (56°C/30 min) (Table II) . Monocytes exposed to saline-treated zymosan generated no MMS. Zymosan that had been incubated in heat-inactivated sera failed to stimulate monocytes to generate MMS. Only zymosan that was activated in normal human sera caused the monocytes to release MMS. Thus, complement products are required for zymosan to induce MMS release from peripheral monocytes.
To examine whether complement-derived factors were the only opsonins adequate for inducing MMS release, we examined the effect of using S. aureus that contains protein A. A ratio of 10 bacteria per monocyte was used (Table II) , and this incubation also led to MMS release. However, incubation of monocytes with staphylococci that were deficient in protein A failed to cause MMS release.
Dose response of MMS. MMS collected from monocytes incubated with activated zymosan for 8 h was added to airway cultures in dose-response experiments (Table III) . In two separate experiments, MMS in amounts ranging from 0.5 to 2 ml (diluted to a final volume of 2 ml) added to airways caused a dose-related increase in mucus release.
Is MMS preformed or newly synthesized? Monocytes were exposed to activated zymosan or S. aureus for 1 h; the cultures were washed and then incubated for 8 h in order to produce a supernatant with mucus secretagogue activity (Table IV) . After the supernatant was collected, the monocytes were removed from the culture plate and lysed; then the lysate was also assayed for MMS activity. The supernatants and lysates from monocytes that were exposed to nonactivated zymosan were also assessed for MMS activity as were lysates of purified monocytes that had never been cultured in vitro. Only the supernatants from monocytes exposed to opsonized zymosan or S. aureus contained secretagogue activity; none was observed in control cultures or in cultures exposed to nonactivated zymosan. Monocyte lysates from all of these preparations failed to affect mucous glycoprotein release.
As it was possible that enzymes contained in the monocyte lysates might be capable of degrading MMS and thereby falsely obscure MMS activity in the lysates, monocyte lysates were These data suggested that MMS activity, as was found with macrophage-derived secretagogues (12) , might be newly synthesized after exposure to the phagocytic stimuli. To examine this possibility further, mononuclear cells were incubated for 16 h in the presence or absence of cycloheximide and then exposed to either activated zymosan or S. aureus. The capacity of these cells to generate MMS activity was then compared to noncycloheximide-exposed controls (Table V) . Mononuclear cells that were exposed to phagocytic stimuli released MMS activity, while cycloheximide-exposed mononuclear cells released much less. While these data suggested that cycloheximide interfered with MMS synthesis, cell lysates were also examined to determine whether intracellular MMS was generated and then not released. No intracellular MMS was detected. These observations strongly suggest that MMS is newly synthesized through a cycloheximide-sensitive pathway. Is MMS a lipid or eicosanoid? Mononuclear cells were exposed to the cyclooxygenase inhibitors, acetylsalicylic acid (100 gg/ml) or indomethacin (10 gg/ml) ( To be certain that other eicosanoids were not contributing to the secretagogue activity, a 50-ml preparation of MMS-rich supernatant was generated from the culture of 75 X 106 monocytes and after acidification, extracted into the organic solvents ethylacetate or diethylether. Neither of the solvents, despite their capacity to extract prostaglandins, monohydroxyeicosatetraenoic acids (HETEs), and leukotrienes, was able to remove MMS activity from the aqueous phase. In two experiments where diethylether was used, the original crude MMS activity on mucus release was +32±6.0% before extraction. After extraction with diethylether, the aqueous phase maintained most of the MMS activity (+28±4.0% above control), whereas the organic phase contained very little activity (+5±3.0% above control). In the two experiments where ethylacetate was used as the organic solvent, the original MMS activity, when assayed on human airways, showed a +35±1.0% increase in mucus release above control. After extraction with ethylacetate, the aqueous phase contained all of the MMS activity (34±3.0o above control) and the organic phase had none (+2±2.0% above control). MMS generation is thus not affected by inhibition of arachidonate metabolism nor extracted into the organic solvents commonly used in eicosanoid purification. Partially purified MMS (see below) was assayed for the presence of immunoreactive PGF2,, PGE, and thromboxane B2 using radioimmunoassays sensitive to 2.5 pg/ml for each. No Over the course of these experiments, eight separate preparations of MMS (after ultramembrane fractionation) have been filtered through Sephadex G-25. Fig. 3 presents the chromatographic pattern from the first three preparations, which suggested that the major portion of MMS activity fractionated with an approximate molecular size of 2,000 D. The MMS activity of Sephadex G-25 fractions 24-26 have been analyzed in five subsequent fractionations and the mean (±SEM) increase in mucus release by these fractions is 43±2.0%. Material from a single isolation prepared by sequential ultramembrane and gel filtration was examined and found to stimulate mucus secretion in a dose-dependent fashion.
Preparations of MMS were sequentially prepared by ultramembrane and gel filtration before horizontal isoelectric focusing on a Pevikon bed. Two separate preparations of MMS after isoelectric focusing are presented in Fig. 4 . In both instances, the major peak of activity focused at pH 5.20. A third preparation of MMS also focused at pH 5.20 (data not shown), indicating that this is a highly reproducible finding. A second smaller peak of activity at pH 7.4 was also consistently noted. Two preparations of partially purified MMS, after ultramembrane and gel filtration and isoelectric focusing, were examined and also found to stimulate mucus secretion in a dose-related fashion.
Discussion
It has recently been demonstrated that human pulmonary macrophages synthesize a factor (MMS) that is capable of Figure 3 . Sephadex G-25 chromatography. 50-100 ml of supernatant that was obtained from monocytes incubated with activated zymosan were pooled and concentrated by ultramembrane filtration. The sample was then applied to a I X 60-cm Sephadex G-25 column that was eluted with distilled water. The figure presents a summary of three separate chromatograms. 
